Sign in
CompletedNo phase

Liver Fibrosis Risk With Methotrexate Exposure

Key facts

Who runs it
Vastra Gotaland Region
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
200 people enrolled
Started
1 Jun 2023
Ended
30 Apr 2025
Type of study
Observational, 2 groups
Record updated
10 November 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients with a diagnosis of RA or PsA followed at the Department of Rheumatology at Sahlgrenska University Hospital, Gothenburg, Sweden
  • Age 18-70
  • Ongoing treatment with methotrexate
  • Available data of MTX initiation date, treatment duration and cumulative exposure

Who cannot take part

  • other rheumatic diseases than RA och PsA
  • known chronic liver disease
  • active hepatitis B or C infection

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

METOHEP is a cross-sectional observational study with the aim to study associations of methotrexate (MTX) exposure and metabolic characteristics with non-invasive liver stiffness and steatosis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

The 2 groups in the trial

  • Patients with RA and PsA

    Patients receiving MTX at assessment, for whom MTX initiation, current weekly dose, treatment duration and cumulative exposure could be established.

  • Reference group

    Patients with RA or PsA with no prior methotrexate exposure

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comprehensive Assessment of Risk for Liver Fibrosis in Long-term Methotrexate Therapy (METOHEP)
Record updated
10 November 2026